These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 20854187)
1. Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma. Przewratil P; Sitkiewicz A; Andrzejewska E Growth Factors; 2010 Dec; 28(6):417-25. PubMed ID: 20854187 [TBL] [Abstract][Full Text] [Related]
2. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism. Emanuele E; Orsi P; Barale F; di Nemi SU; Bertona M; Politi P Clin Biochem; 2010 Feb; 43(3):317-9. PubMed ID: 19850021 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report. Przewratil P; Sitkiewicz A; Wyka K; Andrzejewska E Pediatr Dermatol; 2009; 26(4):399-404. PubMed ID: 19689513 [TBL] [Abstract][Full Text] [Related]
5. Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery. Shantha Kumara HM; Cabot JC; Hoffman A; Luchtefeld M; Kalady MF; Hyman N; Feingold D; Baxter R; Whelan RL Surg Endosc; 2010 Feb; 24(2):283-9. PubMed ID: 19551437 [TBL] [Abstract][Full Text] [Related]
6. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902 [TBL] [Abstract][Full Text] [Related]
7. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Molskness TA; Stouffer RL; Burry KA; Gorrill MJ; Lee DM; Patton PE Hum Reprod; 2004 Apr; 19(4):822-30. PubMed ID: 15033950 [TBL] [Abstract][Full Text] [Related]
8. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688 [TBL] [Abstract][Full Text] [Related]
9. Expression, localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis. Frysz-Naglak D; Fryc B; Klimacka-Nawrot E; Mazurek U; Suchecka W; Kajor M; Kurek J; Stadnicki A Int Immunopharmacol; 2011 Feb; 11(2):220-5. PubMed ID: 21115119 [TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study. Seet RC; Chow AW; Quek AM; Chan YH; Lim EC Int J Infect Dis; 2009 Sep; 13(5):e248-53. PubMed ID: 19261502 [TBL] [Abstract][Full Text] [Related]
11. Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Przewratil P; Sitkiewicz A; Andrzejewska E Cytokine; 2010 Feb; 49(2):141-7. PubMed ID: 20015661 [TBL] [Abstract][Full Text] [Related]
12. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Jaroszewicz J; Januszkiewicz M; Flisiak R; Rogalska M; Kalinowska A; Wierzbicka I Cytokine; 2008 Oct; 44(1):14-7. PubMed ID: 18656381 [TBL] [Abstract][Full Text] [Related]
13. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients. Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease. Pohl-Schickinger A; Koehne P; Schmitz T; Schmitt KR; Hübler M; Redlin M; Berger F; Stiller B Cardiol Young; 2010 Oct; 20(5):505-8. PubMed ID: 20470449 [TBL] [Abstract][Full Text] [Related]
16. Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Shantha Kumara HM; Cabot JC; Hoffman A; Luchtefeld M; Kalady MF; Hyman N; Feingold D; Baxter R; Whelan RL Surg Endosc; 2009 Apr; 23(4):694-9. PubMed ID: 19184203 [TBL] [Abstract][Full Text] [Related]
17. Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1 and R2) in patients with adrenal cortex tumours treated by surgery. Jurczyńska J; Stepień T; Lawnicka H; Stepień H; Krupiński R; Kołomecki K; Kuzdak K; Komorowski J Endokrynol Pol; 2009; 60(1):9-13. PubMed ID: 19224499 [TBL] [Abstract][Full Text] [Related]
18. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Aref S; El Sherbiny M; Goda T; Fouda M; Al Askalany H; Abdalla D Hematology; 2005 Apr; 10(2):131-4. PubMed ID: 16019458 [TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer. Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579 [TBL] [Abstract][Full Text] [Related]
20. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin]. Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]